At a glance
- Class
- Amylin / calcitonin receptor agonist
- Receptor targets
- Amylin and calcitonin receptors
- Length
- 37 amino acids (acylated amylin analogue)
- Molecular mass
- ≈ 4.41 kDa
- Origin
- Synthetic analogue of human amylin
- Research area
- Metabolic & incretin research
- Also known as
- AM833
What Cagrilintide is
Amylin is a hormone released from the pancreas alongside insulin. Native amylin is cleared quickly and tends to clump into fibrils, so cagrilintide changes several residues and adds a fatty diacid chain, which gives it a half-life measured in days.
It activates amylin and calcitonin receptors, a different mechanism from GLP-1, GIP or glucagon. Most current interest comes from its pairing with semaglutide, a combination Novo Nordisk has submitted to the FDA.
What the research literature studies
- Amylin and calcitonin receptor activation in cell-based assays
- Fibril formation: why native amylin aggregates and how substitutions reduce it
- Albumin binding after fatty-diacid acylation
Evidence rating: 4/5
Late-stage human trials. Phase 3 data exist, mainly for the combination with semaglutide. Not yet approved. See our methodology for how levels are assigned.
- Most late-stage data are for the CagriSema combination, so results cannot be attributed to cagrilintide alone.
- Regulatory status is changing quickly. Re-check before relying on any approval claim.
Regulatory status
Cagrilintide has not been approved by any regulator as a standalone medicine. The cagrilintide and semaglutide combination (CagriSema) was submitted to the FDA in December 2025 and was still under review at the time of writing. Research-grade material is not a medicine and must not be used in people or animals.
Reviewed November 2026.
Cagrilintide at Nordapep: sizes and price per mg
Every size, its price and the cost per milligram, so you can choose the best-value vial for your protocol.
Not currently listed at Nordapep.
Compare Cagrilintide
Cagrilintide FAQ
What is CagriSema?
A fixed-dose combination of cagrilintide and semaglutide developed by Novo Nordisk. It is not approved at the time of writing.
How is cagrilintide different from semaglutide?
Cagrilintide mimics amylin and acts on amylin and calcitonin receptors. Semaglutide mimics GLP-1 and acts on the GLP-1 receptor. See the comparison page.
Where can I buy Cagrilintide for research?
Nordapep does not currently list Cagrilintide. You can ask Nordapep about availability, or compare related compounds that are in stock.
Is Cagrilintide approved?
Cagrilintide has not been approved by any regulator as a standalone medicine. The cagrilintide and semaglutide combination (CagriSema) was submitted to the FDA in December 2025 and was still under review at the time of writing. Research-grade material is not a medicine and must not be used in people or animals.
Key terms for Cagrilintide
Further reading
Cite this page
peptide.wiki. (2026). Cagrilintide: research peptide profile. peptide.wiki. https://www.peptide.wiki/peptides/cagrilintide